Immutrin
Latest round
- Series A
Last raised
- Nov 2026
Total raised
- $173M
Investors
- 9
About Immutrin
Based in the UK, and founded in 2019 co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ, Immutrin Ltd specializes in developing innovative antibody therapies aimed at treating ATTR cardiomyopathy, a severe form of amyloidosis, with a focus on improving patient outcomes. Immutrin Ltd, headquartered in Cambridge, UK, is a biotechnology company dedicated to addressing the challenges of ATTR cardiomyopathy through its proprietary antibody therapy. Mihriban Tuna is the current CEO of this company. Immutrin’s core product offering centers around its proprietary antibody therapy developed for the treatment of ATTR cardiomyopathy, a severe and progressive form of amyloidosis. The therapy operates through a unique mechanism designed to selectively and exclusively remove established amyloid fibrils, addressing a critical need in the management of this condition. This innovative solution aims to improve patient outcomes by reversing the adverse effects of amyloidosis on cardiovascular health. Immutrin targets healthcare providers and hospitals specializing in cardiology and hematology, focusing on markets in North America, Europe, and Asia, where the prevalence of amyloidosis conditions warrants advanced therapeutic options. Immutrin generates revenue primarily through partnerships and collaborations with healthcare institutions and biopharmaceutical companies engaged in the treatment of amyloidosis. The business model is structured around licensing agreements and joint ventures that facilitate the development and distribution of its flagship antibody therapy. Revenue streams may include milestone payments, royalties from product sales, and potential profit-sharing arrangements. Given the specialized nature of the therapeutic market, transactions typically involve direct engagement with healthcare providers, ensuring that the therapy reaches patients who benefit from its unique attributes in treating ATTR cardiomyopathy. Immutrin Ltd intends to expand its product portfolio by developing additional therapies targeting other forms of amyloidosis, with plans for product launches in the next 12 to 24 months. The company is also focusing on entering new geographic markets, particularly in Asia and North America, to broaden access to its therapies by the end of 2024.
Who invested in Immutrin
9 investors across 2 rounds
See all investors in Immutrin
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immutrin
Who invested in Immutrin?
Immutrin has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immutrin raised?
Immutrin has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Immutrin last raise money?
Immutrin's most recent round on record is a Series A, in Nov 2026.
What does Immutrin do?
Based in the UK, and founded in 2019 co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ, Immutrin Ltd specializes in developing innovative antibody therapies aimed at treating ATTR cardiomyopathy, a severe form of amyloidosis, with a focus on improving patient outcomes.
Where is Immutrin headquartered?
Immutrin is headquartered in Cambridge, UK.
Which VCs invest in companies like Immutrin?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Immutrin's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immutrin? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.